BioNTech (NASDAQ:BNTX) Trading Down 0.9% - Should You Sell?

BioNTech SE (NASDAQ:BNTX - Get Free Report)'s share price was down 0.9% during trading on Friday . The stock traded as low as $117.79 and last traded at $119.58. Approximately 226,396 shares traded hands during trading, a decline of 72% from the average daily volume of 814,359 shares. The stock had previously closed at $120.72.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BNTX. Jefferies Financial Group upgraded shares of BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a "buy" rating and a $130.00 price target on the stock. HSBC raised their price objective on BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. HC Wainwright reiterated a "buy" rating and set a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Finally, Canaccord Genuity Group raised their target price on shares of BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $138.67.

BioNTech Trading Down 1.9 %

The firm has a market capitalization of $28.38 billion, a PE ratio of -56.94 and a beta of 0.26. The stock's 50-day moving average price is $113.69 and its 200 day moving average price is $98.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm's quarterly revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 EPS. On average, sell-side analysts expect that BioNTech SE will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in the stock. Candriam S.C.A. boosted its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Fred Alger Management LLC acquired a new stake in BioNTech in the third quarter worth about $59,485,000. Baillie Gifford & Co. grew its stake in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after acquiring an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock valued at $2,249,000 after acquiring an additional 7,340 shares in the last quarter. Finally, Discovery Capital Management LLC CT purchased a new position in shares of BioNTech in the 2nd quarter valued at approximately $2,467,000. Institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.